InvestorsHub Logo
Followers 4
Posts 382
Boards Moderated 0
Alias Born 05/11/2016

Re: None

Friday, 09/15/2017 11:05:43 AM

Friday, September 15, 2017 11:05:43 AM

Post# of 2804248
Not sure who's watching but OXISD has been making some waves in the biotech sector with their therapy TriKE. TriKE offers a platform to target ligands that can be incorporated and has the ability to stimulate endogenous NK cells. simply put, this process can bypass the need for cell transfers altogether and make way for a new generation of immunotherapeutics.

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.